Buntanetap for Early Parkinson's Disease
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify that you must stop taking your current medications. However, you need to have stable medications for at least 4 weeks before screening, and certain medications like CYP3A4 inhibitors or inducers are not allowed.
What is the purpose of this trial?
This trial is testing a new pill called buntanetap/posiphen to help people with early Parkinson's Disease. The pill aims to reduce brain inflammation and protect nerve cells, which could improve movement and daily activities. The study will compare the effects of the pill over several months.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily administration of 10 mg or 20 mg of buntanetap/posiphen or placebo for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment, including a 24-hour follow-up call after each clinical visit
Treatment Details
Interventions
- Buntanetap
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Annovis Bio Inc.
Lead Sponsor
TFS Trial Form Support
Industry Sponsor